Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase.

Telomere shortening is associated with disease evolution in chronic myelogenous leukemia (CML). We have examined the relationship between diagnostic telomere length and outcome in 59 patients with CML who entered into the MRC CMLIII Trial by Southern blot hybridization using the (TTAGGG)(4) probe. Age-adjusted telomere repeat array (TRA) reduction was found to significantly correlate with time from diagnosis to acceleration, such that patients with a larger TRA reduction entered the accelerated phase more rapidly (r = -0.50; P =.008). Cox-regression analysis for this group was suggestive of a relationship between a greater TRA-reduction and a shorter time to acceleration (P =.054). Age-adjusted TRA reduction did not significantly affect either the time to blast crisis or overall survival. Our results show that telomere shortening observed at the time of diagnosis in CML significantly influences the time to progress to the accelerated phase. The measurement of diagnostic TRA may prove to be clinically important in the selection of patients at high risk of disease transformation in CML.

[1]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[2]  T. Brümmendorf,et al.  Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry. , 2000, Blood.

[3]  L. Sabatier,et al.  Telomere dynamics, end-to-end fusions and telomerase activation during the human fibroblast immortalization process , 1999, Oncogene.

[4]  K. Ohyashiki,et al.  Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  R. Kusec,et al.  Telomere length shortening is associated with disease evolution in chronic myelogenous leukemia , 1999, American journal of hematology.

[6]  J. Lee,et al.  Telomerase Activity in Human Breast Tumors , 1998 .

[7]  W. Hilbe,et al.  Telomere length and telomerase activity predict survival in patients with B cell chronic lymphocytic leukemia. , 1998, Cancer research.

[8]  J. Tooze,et al.  Progressive Telomere Shortening in Aplastic Anemia , 1998 .

[9]  T. Dexter,et al.  Accelerated telomere shortening in young recipients of allogeneic bone-marrow transplants , 1998, The Lancet.

[10]  J. Shay,et al.  The relationship between telomere length and therapy‐associated cytogenetic responses in patients with chronic myeloid leukemia , 1997, Cancer.

[11]  J. Shay,et al.  Telomerase activity and cytogenetic changes in chronic myeloid leukemia with disease progression , 1997, Leukemia.

[12]  R. Kusec,et al.  Telomere length in myelodysplastic syndromes , 1995, American journal of hematology.

[13]  S. Richards,et al.  UK Medical Research Council randomised, multicentre trial of interferon-αn1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response , 1995, The Lancet.

[14]  B. Leber,et al.  Telomerase activity in normal leukocytes and in hematologic malignancies. , 1995, Blood.

[15]  K. Oshimi,et al.  Telomeric DNA in normal and leukemic blood cells. , 1995, The Journal of clinical investigation.

[16]  C B Harley,et al.  Specific association of human telomerase activity with immortal cells and cancer. , 1994, Science.

[17]  K. Ohyashiki,et al.  Telomere shortening associated with disease evolution patterns in myelodysplastic syndromes. , 1994, Cancer research.

[18]  Z. Estrov,et al.  Chronic Myelogenous Leukemia : A Concise Update , 2003 .

[19]  Robin C. Allshire,et al.  Telomere reduction in human colorectal carcinoma and with ageing , 1990, Nature.

[20]  P. Sperryn,et al.  Blood. , 1989, British journal of sports medicine.

[21]  V A Zakian,et al.  Structure and function of telomeres. , 1989, Annual review of genetics.